Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. Purple Biotech Ltd.
  6. Summary
    PPBT   IL0007650166

PURPLE BIOTECH LTD.

(PPBT)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   End-of-day quote. End-of-day quote Tel Aviv Stock Exchange
01/19/2022 01/20/2022 01/23/2022 01/24/2022 01/25/2022 Date
1.22 1.183 1 0.952 0.916 Last
63018 173585 558962 190655 122542 Volume
-2.40% -3.03% -15.47% -4.80% -3.78% Change
Estimated financial data (e) (USD)
Sales 2019 1,00 M - -
Net income 2019 -5,85 M - -
Net cash position 2019 4,17 M - -
P/E ratio 2019 -2,45x
Yield 2019 -
Sales 2020 1,00 M - -
Net income 2020 -28,0 M - -
Net cash position 2020 56,9 M - -
P/E ratio 2020 -1,60x
Yield 2020 -
Capitalization 163 M 51,2 M -
EV / Sales 2019 10,3x
EV / Sales 2020 10,2x
Nbr of Employees 13
Free-Float 99,9%
More Financials
Company
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose... 
Sector
Pharmaceuticals
Calendar
02/10Earnings Release
More about the company
All news about PURPLE BIOTECH LTD.
01/06PURPLE BIOTECH : Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of ..
PU
01/06Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of..
AQ
01/06Purple Biotech Appoints Ori Hershkovitz to Its Board of Directors
CI
2021PURPLE BIOTECH : Appoints Senior Business Development Executive Fabien Sebille as Chief Bu..
PU
2021Purple Biotech Appoints Fabien Sebille as Chief Business Officer
CI
2021Purple Biotech Initiates Part 2 of Phase 1/2 Trial of NT219 to Treat Multiple Cancers
MT
2021PURPLE BIOTECH : Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evalua..
PU
2021Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evalu..
AQ
2021Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evalu..
CI
2021Notice for the Annual General Meeting of Shareholders of Purple Biotech Ltd. and Proxy ..
PU
2021Purple Biotech Ltd. Announces Retirement of Stern-Raff as Director
CI
20216K : Financial results for the three-month period ended September 30, 2021
PU
2021The Company's Consolidated Unaudited Interim Financial Statements as of September 30, 2..
PU
2021Purple Biotech Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
2021Purple Biotech to Present at the Jefferies London Healthcare Conference
AQ
More news
News in other languages on PURPLE BIOTECH LTD.
01/06Purple Biotech nomme Ori Hershkovitz à son conseil d'administration
2021Purple Biotech lance la deuxième partie de l'essai de phase 1/2 du NT219 pour le traite..
More news
Chart PURPLE BIOTECH LTD.
Duration : Period :
Purple Biotech Ltd. Technical Analysis Chart | PPBT | IL0007650166 | MarketScreener
Income Statement Evolution
Managers and Directors
Isaac Israel Chief Executive Officer & Director
Gil Efron President, Chief Financial Officer & Deputy CEO
Eric K. Rowinsky Chairman
Bertrand C. Liang Chief Medical Officer
Ido Agmon Independent Director